- Home
- EVF vs IMUX Comparison
EVF vs IMUX Comparison
Compare EVF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- IMUX
- Stock Information
- Founded
- EVF 1998
- IMUX 2016
- Country
- EVF United States
- IMUX United States
- Employees
- EVF N/A
- IMUX N/A
- Industry
- EVF Investment Managers
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- IMUX Health Care
- Exchange
- EVF Nasdaq
- IMUX Nasdaq
- Market Cap
- EVF N/A
- IMUX 90.3M
- IPO Year
- EVF N/A
- IMUX N/A
- Fundamental
- Price
- EVF $5.61
- IMUX $1.11
- Analyst Decision
- EVF
- IMUX Strong Buy
- Analyst Count
- EVF 0
- IMUX 6
- Target Price
- EVF N/A
- IMUX $13.20
- AVG Volume (30 Days)
- EVF 93.3K
- IMUX 661.6K
- Earning Date
- EVF 01-01-0001
- IMUX 05-07-2025
- Dividend Yield
- EVF 10.68%
- IMUX N/A
- EPS Growth
- EVF N/A
- IMUX N/A
- EPS
- EVF 0.94
- IMUX N/A
- Revenue
- EVF N/A
- IMUX N/A
- Revenue This Year
- EVF N/A
- IMUX N/A
- Revenue Next Year
- EVF N/A
- IMUX N/A
- P/E Ratio
- EVF $6.74
- IMUX N/A
- Revenue Growth
- EVF N/A
- IMUX N/A
- 52 Week Low
- EVF $5.20
- IMUX $0.83
- 52 Week High
- EVF $6.84
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- EVF 49.48
- IMUX 56.34
- Support Level
- EVF $5.43
- IMUX $0.86
- Resistance Level
- EVF $5.93
- IMUX $1.01
- Average True Range (ATR)
- EVF 0.15
- IMUX 0.09
- MACD
- EVF 0.04
- IMUX 0.02
- Stochastic Oscillator
- EVF 98.82
- IMUX 71.67
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.